Compare Bristol-Myers Squibb Co (BMY) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.84 (market cap $129.94B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | SGOV | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $100.74 |
52-Week Low | $42.60 | $100.28 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.515 with minimal daily movement (+0.01%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators are neutral. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced exposure. The fund provides exposure to ultra-short-term Treasury bonds with monthly distributions, currently yielding approximately 3.8%.
SGOV serves as a defensive cash alternative amid market volatility, offering principal protection and minimal interest rate risk. The fund benefits from rising benchmark rates but faces pressure from potential Fed rate hikes and inflation concerns. Current macro uncertainty and steepened yield curve create both opportunity and risk for Treasury-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
